Armistice Capital, LLC and Steven Boyd filed Amendment No. 2 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of common shares of Arcadia Biosciences, Inc. as of September 30, 2026.
Key Highlights
- Beneficial ownership: Armistice Capital, LLC and Steven Boyd each reported beneficial ownership of 516,624 shares of Arcadia Biosciences common stock.
- Percent of class: The 516,624 shares represent 9.99% of the class, according to the filing.
- Voting and dispositive power: Both reporting persons reported 0 sole voting power and 0 sole dispositive power, with shared voting and shared dispositive power each at 516,624 shares.
- Direct holder: The shares are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and investment advisory client of Armistice Capital.
- Filing event date: The date of the event requiring this filing was September 30, 2026.
- Ordinary course certification: The filing certifies the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."
Armistice Capital and Boyd Disclose Shared 516,624-Share Position in Arcadia Biosciences
According to the filing, Armistice Capital, LLC serves as the investment manager of Armistice Capital Master Fund Ltd., which is the direct holder of the reported shares. Pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities held by the Master Fund and thus may be deemed to beneficially own those securities. Steven Boyd, as the managing member of Armistice Capital, may also be deemed to beneficially own the same securities.
The filing notes that the Master Fund "specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital." The Master Fund is identified as having the right to receive dividends from, or proceeds from the sale of, the reported securities. Armistice Capital is organized in Delaware; Steven Boyd is a United States citizen. The issuer, Arcadia Biosciences, Inc., lists its principal executive offices at 5956 Sherry Lane, Suite 2000, Dallas, Texas 75225.
This Schedule 13G was filed as Amendment No. 2, with the triggering event dated September 30, 2026, and the filing signed and dated November 16, 2026. The filing does not specify which rule under Section 13d-1 (rule (b), (c), or (d)) was checked as applicable, as that portion of the source text was not clearly designated.
What Was Disclosed
Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G disclosing shared beneficial ownership of 516,624 common shares of Arcadia Biosciences, Inc., representing 9.99% of the class, as of September 30, 2026.




Please wait processing your request...